EsoCap AG has announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 10,744,095 on August 18, 2020. The patent is directed at the smart application technology enabling specific site- directed treatment of several diseases of the esophagus.
“Issue of the U.S. patent is a major milestone confirming the novelty of EsoCap’s proprietary technology”, commented Isabelle Racamier, EsoCap AG CEO. “Grant of this patent further bolsters EsoCap’s intellectual property position.“ Under a worldwide agreement, the University of Greifswald in Germany has granted EsoCap the exclusive rights to this unique drug delivery technology developed by the University of Greifswald.
